CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aceragen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aceragen Inc
505 Eagleview Boulevard, Suite 212
Phone: (484) 348-1600p:484 348-1600 EXTON, PA  19341  United States Fax: (617) 679-5592f:617 679-5592
This company ceased filing statements with the SEC on 8/28/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Vincent J.Milano 59 9/28/2022 12/1/2014
Chief Executive Officer, Chief Financial Officer, Director John C.Taylor 53 4/28/2023 9/28/2022
Chief Operating Officer DanielSalain 55 9/28/2022 9/28/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Aceragen, Inc.
Hybridon, Inc.
Idera Pharmaceuticals Inc.

General Information
Number of Employees: 26 (As of 3/31/2023)
Outstanding Shares: 8,420,276 (As of 7/19/2023)
Shareholders: 27
Stock Exchange: NASD
Federal Tax Id: 043072298
Fax Number: (617) 679-5592
Email Address: m.knight@noonanrusso.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024